Association of KCNQ1 polymorphisms with gliclazide efficacy in Chinese type 2 diabetic patients

Duan, Fangfang; Guo, Yu; Zhang, Liuwei; Chen, Peixian; Wang, Xiaozhu; Liu, Zhike; Hu, Yonghua; Chen, Shenren; Chen, Dafang

doi:10.1097/fpc.0000000000000204

Cited by 8 publications

(5 citation statements)

References 31 publications

(46 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the other study published latest, Duan et al found that KCNQ1 rs2237897 was associated with the efficacy of gliclazide accessed by FPG after 8-week monotherapy in Chinese type 2 diabetic patients. Specifically, the FPG reduction and treatment success rate were significantly higher in carriers of rs2237897 CT and TT genotypes, whereas no significant difference was found in the FPG reduction and treatment success rate among different genotype of rs2237892 [19] . Similar with our study, the enrolled patients were newly diagnosed T2DM and treated with gliclazide monotherapy for perspective research.…”

Section: Wwwchinapharcom LI Q Et Almentioning

confidence: 83%

“…Based on the original genome-wide association scans and replication studies, common variants in KCNQ1 (rs2237892, rs2237895, and rs2237897) demonstrate the strongest associations with T2DM [12,13,18,34] . A recent study focusing on Chinese patients with T2DM confirmed that rs2237897 but not rs2237892 is related to the efficacy of gliclazide monotherapy according to FPG alone [19] . Thus far, no studies have reported data for the relationship between rs2237895 and SUs.…”

Section: Discussionmentioning

confidence: 99%

“…Specifically, KCNQ1 channels might play a role in the regulation of insulin secretion and participate in the regulation of cell volume, which is critically important for the regulation of metabolism by insulin [13,[15][16][17][18] . Moreover, it has been reported recently that KCNQ1 rs2237897 is related to the efficacy of gliclazide monotherapy in Chinese patient who are newly diagnosed with type 2 diabetes [19] . Our previous pharmacogenetic study of gliclazide demonstrated that KCNJ11 E23K can influence responses to gliclazide due to its effect on insulin secretion in Chinese patients who are newly diagnosed with T2DM [20] .…”

Section: Abcc8 Kcnj11 Cyp2c9 Tcf7l2 Pparg Irs1 and Nos1apmentioning

confidence: 99%

See 2 more Smart Citations

Polymorphisms of the KCNQ1 gene are associated with the therapeutic responses of sulfonylureas in Chinese patients with type 2 diabetes

Tang

Jiang

et al. 2016

Acta Pharmacol Sin

View full text Add to dashboard Cite

KCNQ1 channel is a member of the voltage-gated potassium channel KQT-like subfamily. The KCNQ1 gene has recently been identified as a susceptibility locus for type 2 diabetes mellitus (T2DM). In the present study, we examined the effects of KCNQ1 variants on the therapeutic response to modified-release gliclazide (gliclazide MR) treatment in Chinese patients newly diagnosed with T2DM. A total of 100 newly diagnosed T2DM patients without a history of any anti-diabetic medications were treated with gliclazide MR for 16 weeks, but 91 patients completed the entire study. The anthropometric parameters were determined at baseline and at the final visit, while clinical laboratory tests were performed at baseline and on weeks 2, 4, 6, 12, 16. Two SNPs, rs2237892 and rs2237895, in the region of the KCNQ1 gene were genotyped in all the participants. All calculations and statistical analyses were conducted using SPSS. The rs2237892 TT homozygotes exhibited significantly higher 2-h glucose levels at baseline (P<0.05) and a lower cumulative attainment rate of the target 2-h glucose level (P log-rank =0.020) than the C allele carriers. Patients with greater numbers of rs2237892 T alleles exhibited larger augmentations (Δ) in the 2-h glucose levels (P=0.027); and patients with the rs2237892 TT genotype exhibited a higher Δ homeostasis model assessment of β-cell function (HOMA-β) than CC and CT genotype carriers (P=0.021 and P=0.043, respectively). Moreover, the rs2237895 C allele was associated with a greater decrement in Δ glycated hemoglobin (HbA1c) (P=0.024); and patients with the CC genotype exhibited greater variance than those with the AA and AC genotypes (P=0.005 and 0.021, respectively). Compared with the C allele, the odds ratio for treatment success among carriers of the rs2237892 T allele was 2.533 (P=0.007); and the rs2237895 C allele was associated with a 2.360-fold decrease in HbA1c compared with the A allele (P=0.009). KCNQ1 polymorphisms are associated with gliclazide MR efficacy in Chinese patients with type 2 diabetes.

show abstract

Section: Wwwchinapharcom LI Q Et Almentioning

confidence: 83%

Section: Discussionmentioning

confidence: 99%

Section: Abcc8 Kcnj11 Cyp2c9 Tcf7l2 Pparg Irs1 and Nos1apmentioning

confidence: 99%

See 1 more Smart Citation

Polymorphisms of the KCNQ1 gene are associated with the therapeutic responses of sulfonylureas in Chinese patients with type 2 diabetes

Tang

Jiang

et al. 2016

Acta Pharmacol Sin

View full text Add to dashboard Cite

show abstract

“…The KCNQ1 rs163184 variant was found to markedly reduce FPG in patients with diabetes on sulfonylurea treatment [ 58 ]. Two studies from China revealed that KCNQ1 polymorphisms are associated with response to sulfonylurea therapy in patients with newly diagnosed T2D [ 59 , 60 ].…”

Section: Pharmacogenomics For Diabetes Mellitusmentioning

confidence: 99%

Pharmacogenomic Studies of Current Antidiabetic Agents and Potential New Drug Targets for Precision Medicine of Diabetes

2020

View full text Add to dashboard Cite

Diabetes is a major threat to people's health and has become a burden worldwide. Current drugs for diabetes have limitations, such as different drug responses among individuals, failure to achieve glycemic control, and adverse effects. Exploring more effective therapeutic strategies for patients with diabetes is crucial. Currently pharmacogenomics has provided potential for individualized drug therapy based on genetic and genomic information of patients, and has made precision medicine possible. Responses and adverse effects to antidiabetic drugs are significantly associated with gene polymorphisms in patients. Many new targets for diabetes also have been discovered and developed, and even entered clinical trial phases. This review summarizes pharmacogenomic evidence of some current antidiabetic agents applied in clinical settings, and highlights potential drugs with new targets for diabetes, which represent a more effective treatment in the future.

show abstract

“…In some studies platelet size and function found to decrease in GAgP patients due to the consumption of large platelets at sites of periodontal inflammation. Platelets may play active role in host response in GAgP patients [58,59].…”

Section: Host Factorsmentioning

confidence: 99%

Aggressive Periodontitis

Alpan¹

2019

Periodontology and Dental Implantology

View full text Add to dashboard Cite

Aggressive periodontitis (AgP) is a disease characterized by rapid loss of periodontal tissues affecting systemically healthy individuals under age of 30 years. AgP classified into two categories named localized and generalized aggressive periodontitis. It differs from chronic periodontitis (CP) depending on age of onset of the disease, rate of progression of the disease, structure and composition of the associated subgingival microflora, changes in host response and familial predisposition. Tissue destruction in patients with AgP is not directly related to bacterial deposits also personal immune response plays a major role in severity of destruction. Surgical and non-surgical techniques can be applied in the treatment of AgP. It is important to treat and obtain frequent controls of individuals with AgP. The main purpose of the treatment is to create a clinical condition that can hold the largest number of teeth in the mouth. After the treatment performed and provided the health of periodontal tissues, patient should be included in the maintenance program.

show abstract

Association of KCNQ1 polymorphisms with gliclazide efficacy in Chinese type 2 diabetic patients

Cited by 8 publications

References 31 publications

Polymorphisms of the KCNQ1 gene are associated with the therapeutic responses of sulfonylureas in Chinese patients with type 2 diabetes

Polymorphisms of the KCNQ1 gene are associated with the therapeutic responses of sulfonylureas in Chinese patients with type 2 diabetes

Pharmacogenomic Studies of Current Antidiabetic Agents and Potential New Drug Targets for Precision Medicine of Diabetes

Aggressive Periodontitis

Contact Info

Product

Resources

About